|
|
| Nomenclature |
|
Symbol:
|
Tg(Thy1-APP*)2.2Ingm
|
|
Name:
|
transgene insertion 2.2, Ingenium Pharmaceuticals
|
|
MGI ID: |
MGI:5294353 |
|
Synonyms: |
TBA2.2 |
|
Transgene:
|
Tg(Thy1-APP*)2.2Ingm
Location:
unknown
Genetic Position: Chr12,
Syntenic
|
|
Transgene
origin |
|
Strain of Origin:
|
Not Specified
|
|
Transgene
description |
|
Transgene
Type: | |
Transgenic (random, expressed) |
|
Mutation: | |
Insertion |
| |
|
Mutation details: The Thy1 regulatory sequence directs expression of a fusion protein of the pre-pro-peptide of murine thyrotropin releasing hormone and the N terminus of the modified human amyloid beta polypeptide, Abeta(Q3?42). This transgene expresses an N terminally truncated A beta protein that is glutamate to glutamine modified at position 3 and engineered to liberate its product preferentially within the secretory pathway. Multiple copies of the transgene inserted into Chr. 12 at 53.5 Mbp with a 2?4 kbp deletion. No effect on the expression of neighboring genes (Heatr5a, Arhgap5 and Akap6) was detected. Maximal transgene expression was seen between P12 and P28. (J:176575)
|
|
Phenotypes
|
View phenotypes for all genotypes (concatenated display).
|
|
Disease models
|
|
| Find Mice (IMSR) |
Mouse strains and cell lines available from the
International Mouse Strain Resource
(IMSR)
|
Carrying this Mutation: |
Mouse Strains: 0 strains available
Cell Lines: 0 lines available |
|
| References |
|
Original: |
J:176575
Alexandru A et al.,
"Selective Hippocampal Neurodegeneration in Transgenic Mice Expressing Small Amounts of Truncated A{beta} Is Induced by Pyroglutamate-A{beta} Formation."
J Neurosci 2011 Sep 7;31(36):12790-12801
|
|
All: |
1 reference(s)
|
|
Analysis Tools
